DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment ; volume:7 ; number:5 ; day:8 ; month:7 ; year:2005 ; pages:1-9 ; date:9.2005
Arthritis Research & Therapy ; 7, Heft 5 (8.7.2005), 1-9, 9.2005
- Urheber
-
Vander Cruyssen, Bert
- Beteiligte Personen und Organisationen
-
Van Looy, Stijn
Wyns, Bart
Westhovens, Rene
Durez, Patrick
Van den Bosch, Filip
Veys, Eric M.
Mielants, Herman
De Clerck, Luc
Peretz, Anne
Malaise, Michel
Verbruggen, Leon
Vastesaeger, Nathan
Geldhof, Anja
Boullart, Luc
De Keyser, Filip
SpringerLink (Online service)
- DOI
-
10.1186/ar1787
- URN
-
urn:nbn:de:1111-201605033143
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vander Cruyssen, Bert
- Van Looy, Stijn
- Wyns, Bart
- Westhovens, Rene
- Durez, Patrick
- Van den Bosch, Filip
- Veys, Eric M.
- Mielants, Herman
- De Clerck, Luc
- Peretz, Anne
- Malaise, Michel
- Verbruggen, Leon
- Vastesaeger, Nathan
- Geldhof, Anja
- Boullart, Luc
- De Keyser, Filip
- SpringerLink (Online service)
Ähnliche Objekte (12)
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Steroid-Refractory Acute Severe Ulcerative Colitis in Infliximab-Experienced Patients
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Predictors of infusion reactions during infliximab treatment in patients with arthritis
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab in young paediatric IBD patients: it is all about the dosing
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Steroid-Refractory Acute Severe Ulcerative Colitis in Infliximab-Experienced Patients
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Predictors of infusion reactions during infliximab treatment in patients with arthritis
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab in young paediatric IBD patients: it is all about the dosing
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Steroid-Refractory Acute Severe Ulcerative Colitis in Infliximab-Experienced Patients
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Predictors of infusion reactions during infliximab treatment in patients with arthritis
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab in young paediatric IBD patients: it is all about the dosing
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients